285 related articles for article (PubMed ID: 34029682)
1. Oral Ferric Maltol for the Treatment of Iron-Deficiency Anemia in Patients With CKD: A Randomized Trial and Open-Label Extension.
Pergola PE; Kopyt NP
Am J Kidney Dis; 2021 Dec; 78(6):846-856.e1. PubMed ID: 34029682
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial.
Howaldt S; Domènech E; Martinez N; Schmidt C; Bokemeyer B
Inflamm Bowel Dis; 2022 Mar; 28(3):373-384. PubMed ID: 33988236
[TBL] [Abstract][Full Text] [Related]
3. Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study.
Schmidt C; Ahmad T; Tulassay Z; Baumgart DC; Bokemeyer B; Howaldt S; Stallmach A; Büning C;
Aliment Pharmacol Ther; 2016 Aug; 44(3):259-70. PubMed ID: 27237709
[TBL] [Abstract][Full Text] [Related]
4. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program.
Gasche C; Ahmad T; Tulassay Z; Baumgart DC; Bokemeyer B; Büning C; Howaldt S; Stallmach A;
Inflamm Bowel Dis; 2015 Mar; 21(3):579-88. PubMed ID: 25545376
[TBL] [Abstract][Full Text] [Related]
5. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.
Block GA; Fishbane S; Rodriguez M; Smits G; Shemesh S; Pergola PE; Wolf M; Chertow GM
Am J Kidney Dis; 2015 May; 65(5):728-36. PubMed ID: 25468387
[TBL] [Abstract][Full Text] [Related]
6. Effect of Ferric Citrate versus Ferrous Sulfate on Iron and Phosphate Parameters in Patients with Iron Deficiency and CKD: A Randomized Trial.
Womack R; Berru F; Panwar B; Gutiérrez OM
Clin J Am Soc Nephrol; 2020 Sep; 15(9):1251-1258. PubMed ID: 32694162
[TBL] [Abstract][Full Text] [Related]
7. Randomized Open-Label Phase 1 Study of the Pharmacokinetics of Ferric Maltol in Inflammatory Bowel Disease Patients with Iron Deficiency.
Bokemeyer B; Krummenerl A; Maaser C; Howaldt S; Mroß M; Mallard N
Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):229-238. PubMed ID: 27101422
[TBL] [Abstract][Full Text] [Related]
8. Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia.
Fishbane S; Block GA; Loram L; Neylan J; Pergola PE; Uhlig K; Chertow GM
J Am Soc Nephrol; 2017 Jun; 28(6):1851-1858. PubMed ID: 28082519
[TBL] [Abstract][Full Text] [Related]
9. The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale.
Macdougall IC; Dahl NV; Bernard K; Li Z; Batycky A; Strauss WE
BMC Nephrol; 2017 Apr; 18(1):117. PubMed ID: 28372549
[TBL] [Abstract][Full Text] [Related]
10. Ferric Maltol: A New Oral Iron Formulation for the Treatment of Iron Deficiency in Adults.
Khoury A; Pagan KA; Farland MZ
Ann Pharmacother; 2021 Feb; 55(2):222-229. PubMed ID: 32633548
[TBL] [Abstract][Full Text] [Related]
11. Iron Replacement Therapy with Oral Ferric Maltol: Review of the Evidence and Expert Opinion.
Schmidt C; Allen S; Kopyt N; Pergola P
J Clin Med; 2021 Sep; 10(19):. PubMed ID: 34640466
[TBL] [Abstract][Full Text] [Related]
12. Ferric maltol Real-world Effectiveness Study in Hospital practice (FRESH): clinical characteristics and outcomes of patients with inflammatory bowel disease receiving ferric maltol for iron-deficiency anaemia in the UK.
Cummings JF; Fraser A; Stansfield C; Beales I; Sebastian S; Hoque S
BMJ Open Gastroenterol; 2021 Feb; 8(1):. PubMed ID: 33622683
[TBL] [Abstract][Full Text] [Related]
13. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.
Macdougall IC; Strauss WE; McLaughlin J; Li Z; Dellanna F; Hertel J
Clin J Am Soc Nephrol; 2014 Apr; 9(4):705-12. PubMed ID: 24458078
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of Oral Ferric Citrate in Patients With Iron-Deficiency Anemia and Chronic Kidney Disease With or Without Heart Failure.
McCullough PA; Uhlig K; Neylan JF; Pergola PE; Fishbane S
Am J Cardiol; 2018 Aug; 122(4):683-688. PubMed ID: 29961562
[TBL] [Abstract][Full Text] [Related]
15. Novel Oral Iron Therapies for Iron Deficiency Anemia in Chronic Kidney Disease.
Pergola PE; Fishbane S; Ganz T
Adv Chronic Kidney Dis; 2019 Jul; 26(4):272-291. PubMed ID: 31477258
[TBL] [Abstract][Full Text] [Related]
16. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
Ziedan A; Bhandari S
Trials; 2019 Apr; 20(1):194. PubMed ID: 30947751
[TBL] [Abstract][Full Text] [Related]
17. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
Lyseng-Williamson KA; Keating GM
Drugs; 2009; 69(6):739-56. PubMed ID: 19405553
[TBL] [Abstract][Full Text] [Related]
18. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.
Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Nolen JG; Roger SD;
Nephrol Dial Transplant; 2014 Nov; 29(11):2075-84. PubMed ID: 24891437
[TBL] [Abstract][Full Text] [Related]
19. Recent and Emerging Therapies for Iron Deficiency in Anemia of CKD: A Review.
Bazeley JW; Wish JB
Am J Kidney Dis; 2022 Jun; 79(6):868-876. PubMed ID: 34758368
[TBL] [Abstract][Full Text] [Related]
20. Effect of Intravenous Ferric Carboxymaltose on Hemoglobin Response Among Patients With Acute Isovolemic Anemia Following Gastrectomy: The FAIRY Randomized Clinical Trial.
Kim YW; Bae JM; Park YK; Yang HK; Yu W; Yook JH; Noh SH; Han M; Ryu KW; Sohn TS; Lee HJ; Kwon OK; Ryu SY; Lee JH; Kim S; Yoon HM; Eom BW; Choi MG; Kim BS; Jeong O; Suh YS; Yoo MW; Lee IS; Jung MR; An JY; Kim HI; Kim Y; Yang H; Nam BH;
JAMA; 2017 May; 317(20):2097-2104. PubMed ID: 28535237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
